CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia

Madero-Marroquin, Rafael; Hunter, Ryan W.; Saygin, Caner; Johnston, Hannah; DuVall, Adam S.; Youshanlouei, Hamed Rahmani; Osei, Clinton; Shah, Syed; Stock, Wendy; Gurbuxani, Sandeep; Patel, Anand A.

doi:10.6082/7m29r-8dm92

Published December 28, 2024 | Version v1

Journal article Open

CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia

1. University of Chicago

Background: CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.

Methods: Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).

Results: The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.

Conclusion: Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.

Data availability

Given concerns for medical privacy, data will not be made publicly available. For original data, please contact Anand Patel.

Files